# Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

> **NCT04753606** · PHASE2 · COMPLETED · sponsor: **NewAmsterdam Pharma** · enrollment: 120 (actual)

## Conditions studied

- Dyslipidemias
- High Cholesterol
- Hypercholesterolemia

## Interventions

- **DRUG:** Obicetrapib

## Key facts

- **NCT ID:** NCT04753606
- **Lead sponsor:** NewAmsterdam Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-18
- **Primary completion:** 2021-05-24
- **Final completion:** 2021-08-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04753606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04753606, "Randomized Study of Obicetrapib as an Adjunct to Statin Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04753606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*